Managing the side effects of vemurafenib therapy
A&S Science Previous     Next

Managing the side effects of vemurafenib therapy

Kim Edmonds Research nurse, Royal Marsden Hospital, London
Julie Burton Team lead senior research nurse, Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle
Anna Gittins Oncology research nurse, NCRN, Oxford Radcliffe Hospitals, Oxford
Jackie Hodgetts Nurse clinician, The Christie NHS Foundation Trust, Manchester
Victoria McMorran Skin cancer clinical nurse specialist, Addenbrooke’s Hospital, Cambridge
Cath Morgans Skin cancer clinical nurse specialist, St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London
Negin Sarafraz Clinical trials practitioner, Guy’s and St Thomas’ NHS Foundation Trust, London
Angela Smith Senior research sister, Mount Vernon Hospital, Northwood

Kim Edmonds and colleagues stress the importance of identifying the symptoms of adverse events in patients being treated for metastatic melanoma and outline ways nurses can advise and support this client group

The advice presented in this article reflects the consensus opinion of research and oncology nurses and a clinical trials practitioner involved in managing patients with metastatic malignant melanoma. The nurses met in September 2011 to discuss the side effects they have encountered when patients are taking vemurafenib and to share best practice on how to manage them. As vemurafenib becomes available in clinics following its recent launch in Europe, nurses will need to anticipate and manage the potential adverse events to ensure patients receive the most effective treatment.

Cancer Nursing Practice. 11, 5,14-21. doi: 10.7748/cnp2012.06.11.5.14.c9148

Correspondence

kim.edmonds@rmh.nhs.uk

Conflict of interest

Succinct Healthcare Communications set up the meeting in September 2011 and provided medical writing support, both of which were funded by Roche Products Ltd. Editorial control was retained by the authors

Peer review

This article has been subject to double blind peer review

You need a subscription to read the full article